Tech Company Financing Transactions

Trevi Therapeutics Funding Round

On 7/21/2017, Trevi Therapeutics announced $50.5 million in Series C funding from New Enterprise Associates, Aperture Venture Partners and Lundbeckfond Ventures.

Transaction Overview

Company Name
Trevi Therapeutics
Announced On
7/21/2017
Transaction Type
Venture Equity
Amount
$50,500,000
Round
Series C
Investors

New Enterprise Associates (Lead Investor) (Ed Mathers)

Aperture Venture Partners

Lundbeckfond Ventures

Omega Funds

TPG Biotech (Eran Nadav)

Proceeds Purpose
The Company plans to use the proceeds from the financing to advance the development of Nalbuphine ER, a drug with a dual agonist/antagonist mechanism of action uniquely suited to treating itch associated in various dermatologic, metabolic, hematologic, and neuropathic conditions.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
195 Church St. 14th Floor
New Haven, CT 06510
USA
Phone
(203) 304-2499
Website
www.trevitherapeutics.com
Email Address
[email protected]
Overview
Trevi Therapeutics, Inc. is a drug development company founded in 2011 focused on developing T111 for the severe chronic itching condition known as pruritus. Pruritus is manifested in various dermatological, metabolic, hematologic and neuronal conditions.
Profile
Trevi Therapeutics LinkedIn Company Profile
Social Media
Trevi Therapeutics Company Twitter Account
Company News
Trevi Therapeutics News
Facebook
Trevi Therapeutics on Facebook
YouTube
Trevi Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Jennifer Good
  Jennifer Good LinkedIn Profile  Jennifer Good Twitter Account  Jennifer Good News  Jennifer Good on Facebook
Chief Financial Officer
Christopher Seiter
  Christopher Seiter LinkedIn Profile  Christopher Seiter Twitter Account  Christopher Seiter News  Christopher Seiter on Facebook
Chief Medical Officer
Thomas Sciascia
  Thomas Sciascia LinkedIn Profile  Thomas Sciascia Twitter Account  Thomas Sciascia News  Thomas Sciascia on Facebook
Vice President
Amale Hawi
  Amale Hawi LinkedIn Profile  Amale Hawi Twitter Account  Amale Hawi News  Amale Hawi on Facebook
VP - Bus. Development
Helena Brett-Smith
  Helena Brett-Smith LinkedIn Profile  Helena Brett-Smith Twitter Account  Helena Brett-Smith News  Helena Brett-Smith on Facebook
VP - Bus. Development
Yann Mazabraud
  Yann Mazabraud LinkedIn Profile  Yann Mazabraud Twitter Account  Yann Mazabraud News  Yann Mazabraud on Facebook

 

 

Browse more venture capital transactions:

Prev: 7/21/2017: bioAffinity Technologies venture capital transaction
Next: 7/21/2017: NeuroVia venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.